---
title: "Phytomenadione - Osteoporosis"
sidebar: mydoc_sidebar
permalink: db01022-mesh-d010024-1.html
toc: false 
---


Path ID: `DB01022_MESH_D010024_1`
{% include image.html url="images/db01022-mesh-d010024-1.png" file="db01022-mesh-d010024-1.png" alt="db01022-mesh-d010024-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D014812 | Phytomenadione | Drug |
| UniProt:P02818 | Osteocalcin | Protein |
| GO:0030282 | Bone mineralization | BiologicalProcess |
| MESH:D010024 | Osteoporosis | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Phytomenadione | INCREASES ACTIVITY OF | Osteocalcin |
| Osteocalcin | POSITIVELY REGULATES | Bone Mineralization |
| Bone Mineralization | NEGATIVELY CORRELATED WITH | Osteoporosis |
|---------|-----------|---------|

Comment: Phytomenadione promotes calcification of bones and can be supplemented together with calcium sources in cases of postmenopausal osteoporosis. Additionally phytomenadione may prevent arterial calcification in case of calcium supplementation [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566462/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566462/)

Reference: [https://go.drugbank.com/drugs/DB01022#mechanism-of-action](https://go.drugbank.com/drugs/DB01022#mechanism-of-action){:target="_blank"}